InvestorsHub Logo
Followers 0
Posts 40
Boards Moderated 0
Alias Born 03/13/2011

Re: None

Thursday, 11/07/2024 6:32:53 PM

Thursday, November 07, 2024 6:32:53 PM

Post# of 1673
In conclusion, Leede Financial's maintenance of its Buy rating and US$18 price target reflects confidence in Profound Medical's growth potential following the favorable reimbursement update. The share price at the time of the report of US$7.35 represents a potential return of approximately 145% to the analyst's target price, highlighting the significant upside potential as the company advances its commercialization efforts.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PROF News